Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS), a partner of the ZIKAlliance consortium, announced that it has entered into a collaborative research agreement with Chongqing Zhifei Biological Products Stock Co., Ltd. (Zhifei) for the clinical studies and commercialization of a recombinant Zika virus subunit vaccine developed by IPS-CAS.
5th April 2017 •
comment
Submit an article
We welcome contributions from members. Please submit an article for review by our editorial team.
Upload nowCategories
- Antibiotics (2)
- Asia (4)
- Child Health (1)
- Childhood (1)
- Clinical trials (5)
- Communications (Mesh) (1)
- Community Engagement (3)
- Coronavirus (24)
- COVID-19 (WEPHREN Resources) (14)
- CRF (2)
- Data Management (1)
- Data Management and Statistics (2)
- Disease-specific Guidance (3)
- Epidemics (Mesh) (4)
- Ethics and Informed Consent (1)
- Funding (5)
- Global Health (2)
- Global Health Research Ethics (3)
- Health Inequality (2)
- Health Policy and Management (4)
- Infectious diseases (17)
- Maternal/Fetal health during pregnancy (1)
- Operational/Governance (19)
- Pandemic preparedness (13)
- Pneumonia (3)
- Press Release (2)
- Publications (3)
- Regulations and Guidelines (5)
- Reports (2)
- Resources (11)
- Sampling (2)
- Statistics (1)
- Study Protocols (5)
- Training (9)
- Trial Design (7)
- Trial Management (5)
- Trial Operations (4)
- Vaccine safety (1)
- Workshops (3)